DaVita HealthCare Partners IncFind Ratings Reports
DAVITA HEALTHCARE PARTNERS's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. DAVITA HEALTHCARE PARTNERS has strong liquidity. Currently, the Quick Ratio is 1.56 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 5.38% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||3581.14||3287.97|
|Net Income ($mil)||97.43||-110.62|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||1437.9||1433.64|
|Total Assets ($mil)||18514.2||18366.66|
|Total Debt ($mil)||9117.82||8498.23|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||27.89||28.14|
|Return on Assets||2.58||2.33|
|Return on Equity||10.15||8.63|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||206.39||215.06|
|Div / share||0.0||0.0|
|Book value / share||22.79||23.12|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||941359.0||1084491.0|
BUY. The current P/E ratio indicates a significant premium compared to an average of 21.90 for the Health Care Providers & Services industry and a premium compared to the S&P 500 average of 25.05. For additional comparison, its price-to-book ratio of 3.40 indicates a premium versus the S&P 500 average of 2.81 and a premium versus the industry average of 3.34. The current price-to-sales ratio is well below the S&P 500 average, but above the industry average. Upon assessment of these and other key valuation criteria, DAVITA HEALTHCARE PARTNERS proves to trade at a premium to investment alternatives within the industry.
|DVA 34.95||Peers 21.90||DVA 10.21||Peers 12.23|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
DVA is trading at a significant premium to its peers.
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
DVA is trading at a discount to its peers.
|DVA 17.55||Peers 16.46||DVA 0.16||Peers 0.95|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
DVA is trading at a premium to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
DVA trades at a significant discount to its peers.
|DVA 3.40||Peers 3.34||DVA 12.69||Peers 22.01|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
DVA is trading at a valuation on par with its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, DVA is expected to significantly trail its peers on the basis of its earnings growth rate.
|DVA 1.14||Peers 0.81||DVA 7.93||Peers 14.30|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
DVA is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
DVA significantly trails its peers on the basis of sales growth